Cancer has been and remains one of the major causes of death in the developed world.
The National Cancer Institute estimates that there will be 1,660,290 cases of cancer in the United States in 2013 and that 580,350 people will die of cancer during 2013.
While many of these cases will fall into the well-known categories of breast, prostate and colo-rectal cancer, many of the deaths caused by cancer are due to less frequent, but equally deadly forms of cancer such as pancreatic cancer.
Currently available therapies are often of limited benefit and many cancers remain incurable even though mean survival has increased, so the development of new cancer drugs remains a major focus of the pharmaceutical industry. For many years, the use of human cancer cell lines grown as xenografts in immunodeficient mice has been a standard test for novel anti-cancer compounds. In these studies, the human cancer cell lines are implanted into immunodeficient mice and form tumors. These tumors can then be treated with novel compounds, and the growth of the tumor used to measure the efficacy of the compound as an anti-cancer agent.
Pharma Models LLC also offers syngeneic models in immunocompetent mice and a wide variety of orthotopic and metastatic tumor models based on luciferase- based imaging.
Illustration of the variety of in vivo imaging models available, from left to right, lung cancer, brain cancer, liver cancer, colorectal cancer with liver metastases, cancer in bone marrow and pancreatic cancer.
Pharma Models LLC has considerable experience in executing tumor models for clients in the pharmaceutical industry, including models of liver, pancreatic, ovarian, stomach, renal, head & neck, bladder, breast, prostate, lung, and colorectal cancers.
We also have vast experience in glioma, melanoma, and hematologic malignancy models.
We believe in speed, accuracy and cost-effectiveness.